Urology
DynaCAD Prostate with Quibim QP-Prostate® AI
Fully automated AI-powered prostate MRI analysis
DynaCAD Prostate with Quibim QP-Prostate® AI brings fully automated outputs for prostate MRI analysis into a single platform — including AI-automated segmentation, lesion detection, and suspicion levels*. Designed to help radiologists streamline time-consuming prostate MRI review while keeping AI results accessible within the DynaCAD Prostate workflow.
Integrated prostate cancer care
Precise diagnosis. Confident decisions. Personalized treatment.
Watch the video
Demonstrated results Urology
Unified AI workflow
Review, analyze, and report prostate MRI studies from a single platform. By bringing AI innovation directly into the DynaCAD environment, radiologists can incorporate AI-assisted insights into their workflow without learning new software, onboarding separate AI vendors, or disrupting established clinical processes.
Fully automated MRI analysis
QP-Prostate streamlines prostate MRI interpretation with AI-automated segmentation, lesion detection, and risk classification.¹⁻⁶ By automating time-consuming analysis, segmentation, and reporting tasks, the solution helps improve workflow efficiency while supporting a more streamlined MRI review process.*
Automated prostate segmentation
QP-Prostate provides automated whole-gland prostate segmentation with a clinically validated accuracy of 88%.² By reducing the need for manual contouring, the solution helps streamline MRI analysis and supports a more consistent assessment workflow.
Transforming complex procedures into confident care
Philips offers a comprehensive prostate cancer diagnosis solution in utilizing MR/ultrasound fusion that is in use at 22 of the 25 of the top cancer hospitals in the US.7
Footnotes
- US Food and Drug Administration. QP-Prostate CAD: 510(k) Premarket Notification K242683. US Food and Drug Administration; 2025. Published March 18, 2025.
- Jimenez-Pastor A, Lopez-Gonzalez R, Fos-Guarinos B, et al. Automated prostate multi-regional segmentation in magnetic resonance using fully convolutional neural networks. Eur Radiol. 2023;33(7):5087-5096. doi:10.1007/s00330-023-09410-9
- Data on file. Quibim S.L. QP-Prostate CAD Pivotal Study Validation Results. Internal validation report/presentation. Published 2023.
- Sánchez Iglesias Á, Morillo Macías V, Picó Peris A, et al. Prostate region-wise imaging biomarker profiles for risk stratification and biochemical recurrence prediction. Cancers (Basel). 2023;15(16):4163. doi:10.3390/cancers15164163
- Antolin A, Mast R, Roson N, et al. Combined radiomics, PI-RADS, and clinical model improve significant prostate cancer prediction and guide biopsy decision. Insights Imaging. 2026;17:118. doi:10.1186/s13244-026-02295-4
- Data on file. Quibim S.L. QP-Prostate Suite 1.0.2 Instructions for Use. Document version 1.0.2e. Code REGO-0509en. Quibim S.L.; 2025. DRAFT dated May 22, 2025.
- U.S. News and World Report: 2017 Best Hospitals Ranking (Cancer)
Disclaimer
*Prostate segmentations, ROIs and associated suspicion levels imported from third-party applications are not generated, verified, or validated by Philips DynaCAD. The radiologist must review these results, adjust as needed prior to acceptance, and determine the PI RADS assessment and final interpretation. Quibim QP-Prostate ® AI is a third-party product.
**Available only in the US